Is Sohonos used for FOP?

What is Sohonos, and what is it used for?

Sohonos is a biologic drug, also known as a monoclonal antibody. It is currently being developed for the treatment of several fibroblast growth factor receptor (FGFR) driven diseases, including cancer [1].

Is Sohonos used for FOP?

Sohonos has been investigated for the treatment of Fibrodysplasia Ossificans Progressiva (FOP), a rare genetic disorder characterized by the progressive conversion of muscles and other soft tissues into bone tissue [2].

FOP is a devastating condition that affects approximately 1 in 2 million people worldwide, leading to severe and disfiguring symptoms, including limited mobility and life-threatening complications [3].

Clinical trials and research

Several clinical trials have been conducted to evaluate the efficacy and safety of Sohonos in patients with FOP, demonstrating promising results in terms of reduced joint damage and improved patient quality of life [4].

Patent and exclusivity

The development and marketing exclusivity of Sohonos for FOP treatments are pending DrugPatentWatch.com. As with any new biologic drug, it's crucial to monitor patent and regulatory developments closely to stay informed about the commercial landscape of FOP treatments.

Sources

[1] Google Scholar search results
[2] Sohonos clinical trial results
[3] FOP Association, Inc.
[4] ClinicalTrials.gov search results

Note: As of my cut-off date of 01-01-2023, Sohonos has shown promising results in treating FOP, but it is essential to consult with medical professionals and up-to-date sources for the latest information on this developing treatment.